The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10180 malaria professionals are enjoying the free benefits of MalariaWorld today

ACT

Pyronaridine–artesunate combination therapy for the treatment of malaria

October 26, 2011 - 13:47 -- Kabogo Ndegwa
Author(s): 
Kurth, Florian; Bélard, Sabine; Basra, Arti; Ramharter, Michael
Reference: 
Current Opinion in Infectious Diseases, December 2011 - Volume 24 - Issue 6 - p 564–569

MalariaWorldPyronaridine–artesunate – currently under evaluation by the European Medicines Agency – may become a preferred choice as first-line therapy in malaria endemic regions based on its low cost, long shelf-life, simplified once-daily dosing regimen, proven efficacy against falciparum and vivax malaria, and the parallel clinical development of a paediatric drug formulation.

Medical Condition: 
Medical Treatment: 

Open Access | Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs

October 25, 2011 - 08:43 -- Kabogo Ndegwa
Author(s): 
Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Dieme Y, Rogier C, Wade B, Bercion R, Pradines B
Reference: 
Malaria Journal 2011, 10:310 (20 October 2011)

MalariaWorldThe introduction of ACT in 2002 has not induced a decrease in P. falciparum susceptibility to the drugs DHA, MDAQ and LMF, which are common ACT components. However, the prevalence of P. falciparum isolates with reduced susceptibility has increased for both MQ and DOX.

Country: 
City: 
Medical Condition: 
Medical Treatment: 

Open Access | Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data

October 11, 2011 - 06:51 -- Kabogo Ndegwa
Author(s): 
Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein H
Reference: 
Malaria Journal 2011, 10:292 (7 October 2011)

MalariaWorldCurrently available data provide a scientific basis for the use of mefloquine in small children in the chemoprophylaxis setting and as a part of treatment regimens in children living in endemic areas.

Person: 
Organization: 
Medical Treatment: 

Effects of Lime Juice on Malaria Parasite Clearance

September 29, 2011 - 08:44 -- Kabogo Ndegwa
Author(s): 
S. A. Adegoke, O. A. Oyelami, O. S. Olatunya and L. A. Adeyemi
Reference: 
Phytotherapy Research, Volume 25, Issue 10, pages 1547–1550, October 2011

MalariaWorldIt may therefore be inferred, from this preliminary work, that lime juice when used with the appropriate antimalarial may enhance malaria parasite clearance especially in those with uncomplicated malaria.

Country: 
Medical Condition: 

Open Access | Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya

September 29, 2011 - 07:48 -- Kabogo Ndegwa
Author(s): 
Harriet Lawford, Dejan Zurovac, Laura OReilly, Sarah Hoibak, Alice Cowley, Stephen Munga, John Vulule, Elizabeth Juma, Robert W Snow, Richard Allan
Reference: 
Malaria Journal 2011, 10:281 (23 September 2011)

MalariaWorldOverall, adherence to AL was found to be low in both Garissa and Bunyala districts, with patient knowledge of the AL dosing regimen found to be the strongest predictor of adherence.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

August 30, 2011 - 11:32 -- Kabogo Ndegwa
Author(s): 
Khalil IF, Alifrangis M, Recke C, Hoegberg LC, Ronn A, Bygbjerg IC, Koch C
Reference: 
Malaria Journal 2011, 10:249 (24 August 2011)

The developed ELISA can be used for quality screening of CQ in pharmaceutical formulations and for drug monitoring in malaria and in other infectious diseases, such as HIV, where CQ proved to be an effective therapeutic agent.

Medical Condition: 
Medical Treatment: 

Open Access | Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia

August 24, 2011 - 09:30 -- Kabogo Ndegwa
Author(s): 
Yeung S, Patouillard E, Allen H, Socheat D
Reference: 
Malaria Journal 2011, 10:243 (18 August 2011)

Whilst some populations have recently experienced dramatic declines in malaria, the majority of those most at risk of Plasmodium falciparum malaria still lack access to effective treatment with artemisinin combination therapy (ACT) and others are already facing parasites resistant to artemisinins.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Feasibility and acceptability of ACT for the community case management of malaria in urban settings in five African sites

August 19, 2011 - 09:13 -- Patrick Sampao
Author(s): 
Akweongo P, Agyei-Baffour P, Sudhakar M, Simwaka BN, Konate AT, Adongo PB, Browne EN, Tegegn A, Ali D, Traore A, Amuyunzu-Nyamongo M, Pagnoni F, Barnish G
Reference: 
Malaria Journal 2011, 10:240 (16 August 2011)

In all sites, interviews revealed that caregivers' knowledge of malaria signs and symptoms improved after the intervention. Preference for CMDs as providers for malaria increased in all sites.

Continent: 
Medical Condition: 
Medical Treatment: 

Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria

August 18, 2011 - 11:30 -- Kabogo Ndegwa
Author(s): 
David Sinclair, Nithya Gogtay, Felicity Brand, Piero Olliaro
Reference: 
Cochrane Infectious Diseases Group, 6 JUL 2011

Two authors independently assessed trials for eligibility and risk of bias, and extracted data.

Medical Condition: 
Medical Treatment: 

Open Access | Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT)

August 17, 2011 - 07:31 -- Kabogo Ndegwa
Author(s): 
Ringsted FM, Massawe IS, Lemnge MM, Bygbjerg IC
Reference: 
Malaria Journal 2011, 10:238 (15 August 2011)

In community practice, the saleability of ACT was negligible. SP was best-selling, and use was not reserved for IPTp, as stipulated in the national anti-malarial policy.

Country: 
Medical Condition: 

Pages

Subscribe to RSS - ACT